Progress in treatment and risk stratification of neuroblastoma: Impact on future clinical and basic research

Seminars in Cancer Biology

Volumn 21, Issue 4, 2011, Pages 217-228

  Øra, Ingrid ^a,b   Eggert, Angelika ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Clinical trial; Collaboration; International Neuroblastoma Risk Group Classification; Neuroblastoma; Risk group; Treatment stratification

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; BUSULFAN; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FENRETINIDE; GANGLIOSIDE GD2 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMATINIB; INTERLEUKIN 2 RECEPTOR ANTIBODY; ISOTRETINOIN; IXABEPILONE; MELPHALAN; MONOCLONAL ANTIBODY; NIFURTIMOX; PLATINUM COMPLEX; RAMUCIRUMAB; REBECCAMYCIN; TENIPOSIDE; TOPOTECAN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; ZOLEDRONIC ACID;

AGE DISTRIBUTION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 17Q; CHROMOSOME ABERRATION; DISEASE CLASSIFICATION; DRUG MEGADOSE; EVENT FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FAMILIAL CANCER; GENE AMPLIFICATION; GENE MUTATION; GENETIC PREDISPOSITION; HEREDITY; HIGH RISK POPULATION; HIGH THROUGHPUT SCREENING; HIRSCHSPRUNG DISEASE; HISTOPATHOLOGY; HUMAN; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; OPSOCLONUS MYOCLONUS SYNDROME; OVERALL SURVIVAL; PROTEIN EXPRESSION; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TRANSLATIONAL RESEARCH; WHOLE BODY RADIATION;

ANIMALS; BIOMEDICAL RESEARCH; CHILD; HUMANS; NEUROBLASTOMA; RISK;

EID: 80655124594     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.07.002     Document Type: Review

References (158)

1. Matthay K.K., Reynolds C.P., Seeger R.C., Shimada H., Adkins E.S., Haas-Kogan D., et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009, 27:1007-1013.
2. Ladenstein R., Potschger U., Hartman O., Pearson A.D., Klingebiel T., Castel V., et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 2008, 41(Suppl 2):S118-S127.
3. Moroz V., Machin D., Faldum A., Hero B., Iehara T., Mosseri V., et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2011, 47:561-571.
4. De Bernardi B., Mosseri V., Rubie H., Castel V., Foot A., Ladenstein R., et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer 2008, 99:1027-1033.
5. Hero B., Simon T., Spitz R., Ernestus K., Gnekow A.K., Scheel-Walter H.G., et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008, 26:1504-1510.
6. De Bernardi B., Gerrard M., Boni L., Rubie H., Canete A., Di Cataldo A., et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009, 27:1034-1040.
7. Cohn S.L., Pearson A.D., London W.B., Monclair T., Ambros P.F., Brodeur G.M., et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009, 27:289-297.
8. Haupt R., Garaventa A., Gambini C., Parodi S., Cangemi G., Casale F., et al. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J Clin Oncol 2010, 28:2331-2338.
9. Pearson A.D., Pinkerton C.R., Lewis I.J., Imeson J., Ellershaw C., Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008, 9:247-256.
10. Modak S., Kushner B.H., LaQuaglia M.P., Kramer K., Cheung N.K. Management and outcome of stage 3 neuroblastoma. Eur J Cancer 2009, 45:90-98.
11. Baker D.L., Schmidt M.L., Cohn S.L., Maris J.M., London W.B., Buxton A., et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010, 363:1313-1323.
12. Laverdiere C., Liu Q., Yasui Y., Nathan P.C., Gurney J.G., Stovall M., et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009, 101:1131-1140.
13. Perwein T., Lackner H., Sovinz P., Benesch M., Schmidt S., Schwinger W., et al. Survival and late effects in children with stage 4 neuroblastoma. Pediatr Blood Cancer 2011.
14. Hobbie W.L., Moab S.M., Carlson C.A., Gruccio D., Ginsberg J.P. Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma. Pediatr Blood Cancer 2011, 56:474-476.
15. Quach A., Ji L., Mishra V., Sznewajs A., Veatch J., Huberty J., et al. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer 2011, 56:191-201.
16. Baade P.D., Youlden D.R., Valery P.C., Hassall T., Ward L., Green A.C., et al. Population-based survival estimates for childhood cancer in Australia during the period 1997-2006. Br J Cancer 2010, 103:1663-1670.
17. Gatta G., Zigon G., Capocaccia R., Coebergh J.W., Desandes E., Kaatsch P., et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 2009, 45:992-1005.
18. Robison L.L., Armstrong G.T., Boice J.D., Chow E.J., Davies S.M., Donaldson S.S., et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 2009, 27:2308-2318.
19. Wright J.H. Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J Exp Med 1910, 12:556-561.
20. Rothenberg A.B., Berdon W.E., D'Angio G.J., Yamashiro D.J., Cowles R.A. Neuroblastoma-remembering the three physicians who described it a century ago: James Homer Wright, William Pepper, and Robert Hutchison. Pediatr Radiol 2009, 39:155-160.
21. Gross R.E., Farber S., Martin L.W. Neuroblastoma sympatheticum; a study and report of 217 cases. Pediatrics 1959, 23:1179-1191.
22. Wittenborg M.H. Roentgen therapy in neuroblastoma; a review of seventy three cases. Radiology 1950, 54:679-688.
23. Cushing H., Wolbach S.B. The transformation of a malignant paravertebral sympathicoblastoma into a benign ganglioneuroma. Am J Pathol 1927, 3. 203-167.
24. Koop C.E., Hope J.W., Abir E. Management of nephroblastoma (Wilms' tumor) and abdominal neuroblastoma. CA Cancer J Clin 1964, 14:178-186.
25. Pinkel D., Pratt C., Holton C., James D., Wrenn E., Hustu H.O. Survival of children with neuroblastoma treated with combination chemotherapy. J Pediatr 1968, 73:928-931.
26. Evans A.E., D'Angio G.J., Randolph J. A proposed staging for children with neuroblastoma. Children's Cancer Study Group A. Cancer 1971, 27:374-378.
27. Spix C., Pastore G., Sankila R., Stiller C.A., Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006, 42:2081-2091.
28. Brodeur G.M., Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3:203-216.
29. Maris J.M. Recent advances in neuroblastoma. N Engl J Med 2010, 362:2202-2211.
30. Gestblom C., Grynfeld A., Ora I., Ortoft E., Larsson C., Axelson H., et al. The basic helix-loop-helix transcription factor dHAND, a marker gene for the developing human sympathetic nervous system, is expressed in both high- and low-stage neuroblastomas. Lab Invest 1999, 79:67-79.
31. Triche T.J. Neuroblastoma-biology confronts nosology. Arch Pathol Lab Med 1986, 110:994-996.
32. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B., et al. The international neuroblastoma pathology classification (the Shimada system). Cancer 1999, 86:364-372.
33. Shimada H., Umehara S., Monobe Y., Hachitanda Y., Nakagawa A., Goto S., et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001, 92:2451-2461.
34. Peuchmaur M., d'Amore E.S., Joshi V.V., Hata J., Roald B., Dehner L.P., et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003, 98:2274-2281.
35. Trochet D., O'Brien L.M., Gozal D., Trang H., Nordenskjold A., Laudier B., et al. PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. Am J Hum Genet 2005, 76:421-426.
36. McConville C., Reid S., Baskcomb L., Douglas J., Rahman N. PHOX2B analysis in non-syndromic neuroblastoma cases shows novel mutations and genotype-phenotype associations. Am J Med Genet A 2006, 140:1297-1301.
37. van Limpt V., Schramm A., van Lakeman A., Sluis P., Chan A., van Noesel M., et al. The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene 2004, 23:9280-9288.
38. Raabe E.H., Laudenslager M., Winter C., Wasserman N., Cole K., LaQuaglia M., et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 2008, 27:469-476.
39. Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
40. Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., de Pontual L., Combaret V., et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970.
41. Chiarle R., Voena C., Ambrogio C., Piva R., Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 8:11-23.
42. Chen Q.R., Bilke S., Wei J.S., Whiteford C.C., Cenacchi N., Krasnoselsky A.L., et al. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics 2004, 5:70.
43. Mosse Y.P., Greshock J., Margolin A., Naylor T., Cole K., Khazi D., et al. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 2005, 43:390-403.
44. Spitz R., Oberthuer A., Zapatka M., Brors B., Hero B., Ernestus K., et al. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 2006, 45:1130-1142.
45. Carr J., Bown N.P., Case M.C., Hall A.G., Lunec J., Tweddle D.A. High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genet Cytogenet 2007, 172:127-138.
46. Michels E., Vandesompele J., De Preter K., Hoebeeck J., Vermeulen J., Schramm A., et al. ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 2007, 46:1098-1108.
47. Janoueix-Lerosey I., Schleiermacher G., Michels E., Mosseri V., Ribeiro A., Lequin D., et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009, 27:1026-1033.
48. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., Bishop J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224:1121-1124.
49. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Siegel S.E., Wong K.Y., et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313:1111-1116.
50. Canete A., Gerrard M., Rubie H., Castel V., Di Cataldo A., Munzer C., et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol 2009, 27:1014-1019.
51. Schleiermacher G., Peter M., Michon J., Hugot J.P., Vielh P., Zucker J.M., et al. Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosomes Cancer 1994, 10:275-281.
52. Bown N., Cotterill S., Lastowska M., O'Neill S., Pearson A.D., Plantaz D., et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999, 340:1954-1961.
53. Caron H., Spieker N., Godfried M., Veenstra M., van Sluis P., de Kraker J., et al. Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted. Genes Chromosomes Cancer 2001, 30:168-174.
54. Plantaz D., Vandesompele J., Van Roy N., Lastowska M., Bown N., Combaret V., et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 2001, 91:680-686.
55. Attiyeh E.F., London W.B., Mosse Y.P., Wang Q., Winter C., Khazi D., et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005, 353:2243-2253.
56. Schwab M., Westermann F., Hero B., Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003, 4:472-480.
57. Caren H., Kryh H., Nethander M., Sjoberg R.M., Trager C., Nilsson S., et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A 2010, 107:4323-4328.
58. Caron H., van Sluis P., de Kraker J., Bokkerink J., Egeler M., Laureys G., et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996, 334:225-230.
59. Maris J.M., Weiss M.J., Guo C., Gerbing R.B., Stram D.O., White P.S., et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 2000, 18:1888-1899.
60. Weiss M.J., Guo C., Shusterman S., Hii G., Mirensky T.L., White P.S., et al. Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Med Pediatr Oncol 2000, 35:526-530.
61. Simon T., Spitz R., Faldum A., Hero B., Berthold F. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 2004, 26:791-796.
62. Spitz R., Hero B., Ernestus K., Berthold F. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Med Pediatr Oncol 2003, 41:30-35.
63. Spitz R., Hero B., Ernestus K., Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res 2003, 9:52-58.
64. Simon T., Spitz R., Hero B., Berthold F., Faldum A. Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q. Cancer Lett 2006, 237:215-222.
65. Bown N., Lastowska M., Cotterill S., O'Neill S., Ellershaw C., Roberts P., et al. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol 2001, 36:14-19.
66. Chen S.T., Lee J.C. An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features. Hum Pathol 2008, 39:1854-1858.
67. George R.E., Sanda T., Hanna M., Frohling S., Luther W., Zhang J., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978.
68. Look A.T., Hayes F.A., Nitschke R., McWilliams N.B., Green A.A. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984, 311:231-235.
69. Bowman L.C., Castleberry R.P., Cantor A., Joshi V., Cohn S.L., Smith E.I., et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997, 89:373-380.
70. George R.E., London W.B., Cohn S.L., Maris J.M., Kretschmar C., Diller L., et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005, 23:6466-6473.
71. Bagatell R., Beck-Popovic M., London W.B., Zhang Y., Pearson A.D., Matthay K.K., et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol 2009, 27:365-370.
72. Schneiderman J., London W.B., Brodeur G.M., Castleberry R.P., Look A.T., Cohn S.L. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J Clin Oncol 2008, 26:913-918.
73. Ambros I.M., Brunner B., Aigner G., Bedwell C., Beiske K., Benard J., et al. A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res 2011, 17:792-804.
74. Vandesompele J., Baudis M., De Preter K., Van Roy N., Ambros P., Bown N., et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005, 23:2280-2299.
75. Schleiermacher G., Michon J., Huon I., d'Enghien C.D., Klijanienko J., Brisse H., et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer 2007, 97:238-246.
76. Oberthuer A., Kaderali L., Kahlert Y., Hero B., Westermann F., Berthold F., et al. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Clin Cancer Res 2008, 14:6590-6601.
77. Oberthuer A., Hero B., Berthold F., Juraeva D., Faldum A., Kahlert Y., et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010, 28:3506-3515.
78. Lastowska M., Viprey V., Santibanez-Koref M., Wappler I., Peters H., Cullinane C., et al. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 2007, 26:7432-7444.
79. Schramm A., Mierswa I., Kaderali L., Morik K., Eggert A., Schulte J.H. Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction. Cancer Lett 2009, 282:55-62.
80. Buckley P.G., Alcock L., Bryan K., Bray I., Schulte J.H., Schramm A., et al. Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q-neuroblastoma. Clin Cancer Res 2010, 16:2971-2978.
81. Vermeulen J., De Preter K., Naranjo A., Vercruysse L., Van Roy N., Hellemans J., et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009, 10:663-671.
82. Katzenstein H.M., Kent P.M., London W.B., Cohn S.L. Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol 2001, 19:1047-1055.
83. Plantaz D., Rubie H., Michon J., Mechinaud F., Coze C., Chastagner P., et al. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients-results of the NBL 90 Study of the French Society of Pediatric Oncology. Cancer 1996, 78:311-319.
84. Pranzatelli M.R. The neurobiology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1992, 15:186-228.
85. Rudnick E., Khakoo Y., Antunes N.L., Seeger R.C., Brodeur G.M., Shimada H., et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001, 36:612-622.
86. Pranzatelli M.R., Tate E.D., Swan J.A., Travelstead A.L., Colliver J.A., Verhulst S.J., et al. B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord 2010, 25:238-242.
87. Krug P., Schleiermacher G., Michon J., Valteau-Couanet D., Brisse H., Peuchmaur M., et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 2010, 14:400-409.
88. Brodeur G.M., Pritchard J., Berthold F., Carlsen N.L., Castel V., Castelberry R.P., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11:1466-1477.
89. Matthay K.K., Shulkin B., Ladenstein R., Michon J., Giammarile F., Lewington V., et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010, 102:1319-1326.
90. Beiske K., Burchill S.A., Cheung I.Y., Hiyama E., Seeger R.C., Cohn S.L., et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 2009, 100:1627-1637.
91. Ambros P.F., Ambros I.M., Brodeur G.M., Haber M., Khan J., Nakagawara A., et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009, 100:1471-1482.
92. Hann H.W., Evans A.E., Siegel S.E., Wong K.Y., Sather H., Dalton A., et al. Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res 1985, 45:2843-2848.
93. Quinn J.J., Altman A.J., Frantz C.N. Serum lactic dehydrogenase, an indicator of tumor activity in neuroblastoma. J Pediatr 1980, 97:89-91.
94. Zeltzer P.M., Marangos P.J., Evans A.E., Schneider S.L. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer 1986, 57:1230-1234.
95. Monclair T., Brodeur G.M., Ambros P.F., Brisse H.J., Cecchetto G., Holmes K., et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009, 27:298-303.
96. Simon T., Hero B., Benz-Bohm G., von Schweinitz D., Berthold F. Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer 2008, 50:965-969.
97. London W.B., Castleberry R.P., Matthay K.K., Look A.T., Seeger R.C., Shimada H., et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005, 23:6459-6465.
98. Tanaka M., Kigasawa H., Kato K., Ijiri R., Nishihira H., Aida N., et al. A prospective study of a long-term follow-up of an observation program for neuroblastoma detected by mass screening. Pediatr Blood Cancer 2010, 54:573-578.
99. Kiely E.M. The surgical challenge of neuroblastoma. J Pediatr Surg 1994, 29:128-133.
100. La Quaglia M.P., Kushner B.H., Su W., Heller G., Kramer K., Abramson S., et al. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 2004, 39:412-417. discussion - 7.
101. Rich B.S., McEvoy M.P., Kelly N.E., Oh E., Abramson S.J., Price A.P., et al. Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries. J Pediatr Surg 2011, 46:103-107.
102. Kushner B.H., Kramer K., Modak S., Qin L.X., Cheung N.K. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer 2010, 116:3054-3060.
103. Kushner B.H., Kramer K., Modak S., Cheung N.K. High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan. Pediatr Blood Cancer 2011, 56:403-408.
104. Bagatell R., London W.B., Wagner L.M., Voss S.D., Stewart C.F., Maris J.M., et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2011, 29:208-213.
105. Rubie H., Geoerger B., Frappaz D., Schmitt A., Leblond P., Ndiaye A., et al. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. Eur J Cancer 2010, 46:2763-2770.
106. Berthold F., Boos J., Burdach S., Erttmann R., Henze G., Hermann J., et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005, 6:649-658.
107. Yalcin B., Kremer L.C., Caron H.N., van Dalen E.C. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev 2010, CD006301.
108. Simon T., Berthold F., Borkhardt A., Kremens B., De Carolis B., Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011, 56:578-583.
109. Sung K.W., Ahn H.S., Cho B., Choi Y.M., Chung N.G., Hwang T.J., et al. Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma: the Korean Society of Pediatric Hematology-Oncology experience over 6 years (2000-2005). J Korean Med Sci 2010, 25:691-697.
110. George R.E., Li S., Medeiros-Nancarrow C., Neuberg D., Marcus K., Shamberger R.C., et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006, 24:2891-2896.
111. Gillis A.M., Sutton E., Dewitt K.D., Matthay K.K., Weinberg V., Fisch B.M., et al. Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 2007, 69:858-864.
112. de Kraker J., Hoefnagel K.A., Verschuur A.C., van Eck B., van Santen H.M., Caron H.N. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 2008, 44:551-556.
113. Matthay K.K., Quach A., Huberty J., Franc B.L., Hawkins R.A., Jackson H., et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol 2009, 27:1020-1025.
114. Klingebiel T., Bader P., Bares R., Beck J., Hero B., Jurgens H., et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998, 34:1398-1402.
115. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341:1165-1173.
116. Garaventa A., Luksch R., Lo Piccolo M.S., Cavadini E., Montaldo P.G., Pizzitola M.R., et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003, 9:2032-2039.
117. Villablanca J.G., Krailo M.D., Ames M.M., Reid J.M., Reaman G.H., Reynolds C.P. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006, 24:3423-3430.
118. Yu A.L., Gilman A.L., Ozkaynak M.F., London W.B., Kreissman S.G., Chen H.X., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010, 363:1324-1334.
119. Simon T., Hero B., Faldum A., Handgretinger R., Schrappe M., Klingebiel T., et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011, 11:21.
120. Gilman A.L., Ozkaynak M.F., Matthay K.K., Krailo M., Yu A.L., Gan J., et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 2009, 27:85-91.
121. Shusterman S., London W.B., Gillies S.D., Hank J.A., Voss S.D., Seeger R.C., et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 2010, 28:4969-4975.
122. Perez C.A., Matthay K.K., Atkinson J.B., Seeger R.C., Shimada H., Haase G.M., et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 2000, 18:18-26.
123. Matthay K.K., Sather H.N., Seeger R.C., Haase G.M., Hammond G.D. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989, 7:236-244.
124. Rubie H., De Bernardi B., Gerrard M., Canete A., Ladenstein R., Couturier J., et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol 2011, 29:449-455.
125. Kushner B.H., Kramer K., LaQuaglia M.P., Cheung N.K. Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy. J Pediatr Hematol Oncol 2003, 25:515-519.
126. Garaventa A., Parodi S., De Bernardi B., Dau D., Manzitti C., Conte M., et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer 2009, 45:2835-2842.
127. George R.E., Diller L., Bernstein M.L. Pharmacotherapy of neuroblastoma. Expert Opin Pharmacother 2010, 11:1467-1478.
128. Modak S., Cheung N.K. Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev 2010, 36:307-317.
129. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138.
130. Otto T., Horn S., Brockmann M., Eilers U., Schuttrumpf L., Popov N., et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009, 15:67-78.
131. Shang X., Burlingame S.M., Okcu M.F., Ge N., Russell H.V., Egler R.A., et al. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 2009, 8:2461-2469.
132. Fulda S. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets 2009, 9:729-737.
133. Garcia-Echeverria C., Sellers W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27:5511-5526.
134. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562.
135. Oehme I., Deubzer H.E., Lodrini M., Milde T., Witt O. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs 2009, 18:1605-1617.
136. Minturn J.E., Evans A.E., Villablanca J.G., Yanik G.A., Park J.R., Shusterman S., et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol 2011.
137. Geoerger B., Chisholm J., Le Deley M.C., Gentet J.C., Zwaan C.M., Dias N., et al. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study. Eur J Cancer 2011, 47:230-238.
138. Kushner B.H., Kramer K., Modak S., Yataghene K., Cheung N.K. High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma. Eur J Cancer 2011, 47:84-89.
139. George R.E., Lahti J.M., Adamson P.C., Zhu K., Finkelstein D., Ingle A.M., et al. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2010, 55:629-638.
140. Saulnier Sholler G.L., Bergendahl G.M., Brard L., Singh A.P., Heath B.W., Bingham P.M., et al. A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. J Pediatr Hematol Oncol 2011, 33:25-30.
141. Beaty O., Berg S., Blaney S., Malogolowkin M., Krailo M., Knight R., et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2010, 55:440-445.
142. Jacobs S., Fox E., Krailo M., Hartley G., Navid F., Wexler L., et al. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res 2010, 16:750-754.
143. London W.B., Frantz C.N., Campbell L.A., Seeger R.C., Brumback B.A., Cohn S.L., et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2010, 28:3808-3815.
144. Langevin A.M., Bernstein M., Kuhn J.G., Blaney S.M., Ivy P., Sun J., et al. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2008, 50:577-580.
145. Russell H.V., Groshen S.G., Ara T., Declerck Y.A., Hawkins R., Jackson H.A., et al. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer 2010.
146. Vassal G., Giammarile F., Brooks M., Geoerger B., Couanet D., Michon J., et al. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Societe Francaise d'Oncologie Pediatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer 2008, 44:2453-2460.
147. Fouladi M., Park J.R., Stewart C.F., Gilbertson R.J., Schaiquevich P., Sun J., et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 2010, 28:3623-3629.
148. Bond M., Bernstein M.L., Pappo A., Schultz K.R., Krailo M., Blaney S.M., et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2008, 50:254-258.
149. Jakacki R.I., Hamilton M., Gilbertson R.J., Blaney S.M., Tersak J., Krailo M.D., et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol 2008, 26:4921-4927.
150. Spratlin J.L., Cohen R.B., Eadens M., Gore L., Camidge D.R., Diab S., et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010, 28:780-787.
151. Russell H.V., Strother D., Mei Z., Rill D., Popek E., Biagi E., et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 2007, 30:227-233.
152. Fox E., Aplenc R., Bagatell R., Chuk M.K., Dombi E., Goodspeed W., et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 2010, 28:5174-5181.
153. Fox E., Maris J.M., Cohn S.L., Goodspeed W., Goodwin A., Kromplewski M., et al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol 2010, 66:737-743.
154. Pein F., Pinkerton R., Berthaud P., Pritchard-Jones K., Dick G., Vassal G. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours. Eur J Cancer 2007, 43:2074-2081.
155. Toporski J., Garkavij M., Tennvall J., Ora I., Gleisner K.S., Dykes J.H., et al. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma. Biol Blood Marrow Transplant 2009, 15:1077-1085.
156. Geller J.I., Wall D., Perentesis J., Blaney S.M., Bernstein M. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer 2009, 52:346-350.
157. Simon T., Langler A., Harnischmacher U., Fruhwald M.C., Jorch N., Claviez A., et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. J Cancer Res Clin Oncol 2007, 133:653-661.
158. Bagatell R., Gore L., Egorin M.J., Ho R., Heller G., Boucher N., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 2007, 13:1783-1788.